Key Takeaways
- Novo Nordisk shares gained over 3% following the FDA’s issuance of warning letters to 30 telehealth firms regarding deceptive marketing of GLP-1 drug compounds.
- The telehealth companies promoted compounded semaglutide and tirzepatide as “generic” alternatives to brand-name medications like Wegovy and Zepbound.
- This marks the FDA’s second enforcement wave, continuing a September initiative under Trump’s directive targeting drug advertising practices.
- Recipients of the warning letters have 15 working days to submit written responses detailing their corrective measures.
- Citi Research highlighted the increased significance of these letters, referencing the FDA’s previous referral of Hims & Hers to the Department of Justice.
Novo Nordisk shares advanced more than 3% during Wednesday trading following the FDA’s decision to send warning letters to 30 telehealth firms over deceptive marketing practices related to compounded GLP-1 medications.
The warning letters addressed companies that marketed compounded semaglutide and tirzepatide products with terms such as “generic Zepbound” or “generic Mounjaro.” These names refer to Eli Lilly’s branded tirzepatide medications.
Certain companies created their own trademark names for the compounds without clearly identifying themselves as the compounding entity. The FDA indicated this practice created the false impression that these firms were the original manufacturers.
The regulatory agency stated clearly: compounded medications lack FDA approval and differ fundamentally from generic medications.
“Compounded drugs can be important for overcoming shortages or meeting unique patient needs — but compounders should not try to compound drugs in a way that circumvents FDA’s approval process,” FDA Commissioner Marty Makary said in a statement.
Semaglutide serves as the active component in Novo Nordisk’s Wegovy and Ozempic. Tirzepatide appears in Eli Lilly’s Zepbound and Mounjaro. A limited number of companies also faced citations for deceptive claims regarding liraglutide, which Novo Nordisk markets as Saxenda.
FDA’s Second Enforcement Initiative
This represents the second enforcement wave since the FDA began its regulatory campaign in September. The initial round included companies such as Eli Lilly, Novo Nordisk, and telehealth provider Hims & Hers Health.
The present action follows President Trump’s executive directive to intensify enforcement against direct-to-consumer pharmaceutical advertising. The FDA reports sending thousands of similar letters during the previous six months — exceeding the total volume from the entire prior decade.
Firms receiving these letters must submit written responses within 15 working days, detailing their plans to address the violations.
Hims & Hers continues to feature prominently in this enforcement effort. The FDA issued a warning in February regarding potential action concerning the company’s $49 compounded weight-loss medication. Novo Nordisk filed a lawsuit against the company during that same month.
The FDA additionally forwarded Hims & Hers to the Department of Justice in early February.
Analyst Perspectives
Citi Research emphasized that the most recent warning letters hold greater significance than previous actions due to the intensifying regulatory landscape.
The investment firm referenced the DOJ referral as evidence that more severe penalties may await firms failing to comply with regulations.
Citi further observed that Commissioner Makary has independently indicated plans to limit the active pharmaceutical ingredients available for compounded GLP-1 products. Such restrictions would further constrain the compounding market.
The enforcement timing increases pressure before widespread Medicare coverage for GLP-1 medications begins in the second quarter.
Novo Nordisk shares closed up 3.59% during Wednesday’s trading session.
